The Top 5 Biosimilar Articles for the Week of June 23

June 27, 2025

Here are the top 5 biosimilar articles for the week of June 23, 2025.

Eye on Pharma: CHMP Aflibercept Decision; Omalizumab Results; Dupilumab Biosimilar Deal

June 26, 2025

Increasing Biosimilar Use Reflects Changing Practice in Pediatric IBD Care

June 25, 2025

Omalizumab Biosimilar Matches Reference Product in Chronic Spontaneous Urticaria

June 24, 2025

BioRationality: Questioning Experts and Journals Reporting on Biosimilar Bill to Remove Interchangeability

June 23, 2025

BioRationality—The Missing Rationality in Biosimilar Discussions and the Path Forward

September 23rd 2024

By Sarfaraz K. Niazi, PhD

Article

The article by Sarfaraz K. Niazi, PhD, critiques the irrationality surrounding biosimilars, suggesting that regulatory changes and cost reductions in manufacturing could make biosimilars as affordable as generic drugs.

The Role of Risk-Sharing Models in Biosimilar Adoption

September 22nd 2024

By Cameron Santoro

Video

Ivo Abraham, PhD, RN, University of Arizona Cancer Center, analyzes the need for innovative risk-sharing models to promote biosimilar development and utilization.

French Study Finds High Patient Satisfaction With Adalimumab Biosimilar Treatment for IBD

September 21st 2024

By Deana Ferreri, PhD

Article

An observational study assessing patient satisfaction with adalimumab for inflammatory bowel disease (IBD) reported a high level of satisfaction with all adalimumab product, including biosimilars.

The Top 5 Biosimilar Articles for the Week of September 16

September 20th 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of September 16, 2024.

Trastuzumab Biosimilar and Pertuzumab Effective, Safe in Neoadjuvant Breast Cancer Therapy

September 19th 2024

By Cameron Santoro

Article

The combination of trastuzumab biosimilar and pertuzumab with chemotherapy was effective in treating HER2-positive breast cancer, offering high safety and affordability.

AAM Report: Generics and Biosimilars Savings Reach $445 Billion in 2023, Part 1

September 18th 2024

By Skylar Jeremias

Article

Savings from generic and biosimilar drugs totaled $445 billion in 2023, showing promise for the growth of both markets and highlighting the success of expansion policies for these products, according to a new report from the Association for Accessible Medicines (AAM).

FDA Approves Pavblu for Retinal Conditions

September 17th 2024

By Skylar Jeremias

Article

Amgen’s Pavblu (aflibercept-ayyh) is the fifth biosimilar referencing Eylea (aflibercept) to be approved for American patients with retinal diseases.

Expanding Biosimilar Adoption: Insights and Strategies With Dr Sophia Humphreys

September 16th 2024

By Skylar Jeremias

Article

Sophia Humphreys, PharmD, MHA, BCBBS, director of system formulary management at Sutter Health, discusses the challenges of expanding biosimilars into new therapeutic areas and highlights the role of education, competitive pricing, and integrated delivery networks in improving adoption and market growth.

STADA Credits Biosimilar Expansion for Profitable First Half of 2024

September 15th 2024

By Skylar Jeremias

Article

German biosimilar manufacturer STADA Arzneimittel reported a 9% revenue increase in the first half of 2024, with over €2 billion in sales, driven in part by biosimilar successes and new product launches.

Real-World Study Shows Comparable Outcomes Between CT-P13, Remicade in RA

September 14th 2024

By Deana Ferreri, PhD

Article

A real-world study of the biosimilar infliximab-dyyb (CT-P13; Inflectra) in rheumatoid arthritis (RA) reported the majority of patients who initiated CT-P13 switched from the reference product (Remicade) or another biologic or targeted synthetic disease-modifying antirheumatic drug.